Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study.

Cancer - 1 Apr 2012

Windsor Rachael E, Strauss Sandra J, Kallis Constantinos, Wood Nicholas E, Whelan Jeremy S

Abstract excerpt

BACKGROUND: Osteosarcoma is the most common malignant bone tumor in children and young people. Efficacy of multiagent MAP (methotrexate, doxorubicin [Adriamycin], cisplatin) chemotherapy may be influenced by multiple cellular pathways. This pilot study aimed to investigate the association of 36 candidate genetic polymorphisms in MAP pathway genes with histological response, survival, and grade 3-4 chemotherapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Neoplasms
Share to Cisplatin
Share to Doxorubicin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Germ Cells

Share to Mitomycin

Share to Multidrug Resistance-Associated Protein 2

Share to Osteosarcoma

Share to Pilot Projects

Source

Identifiers

PMID: 21887680
DOI: 10.1002/cncr.26472

Genes

ABCC2
GSTP1
ABCB1
MTHFD1
MTHFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study.PMID 21887680Read ↗

Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 ProtocolSemantic proximity Read ↗

Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma.Semantic proximity Read ↗

Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.Semantic proximity Read ↗

Pharmacogenetics of chemotherapy treatment response and -toxicities in patients with osteosarcoma: a systematic review of 2010-2020Semantic proximity Read ↗

A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment.Semantic proximity Read ↗

Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study.Semantic proximity Read ↗

ABCC2(rs717620), and ABCC3 (rs4793665) affect high dose Methotrexate toxicity, and outcome in children with osteosarcomaSemantic proximity Read ↗

The role of pharmacogenetics in the treatment of osteosarcomaSemantic proximity Read ↗

CYP Genotypes Are Associated with Toxicity and Survival in Osteosarcoma Patients.Semantic proximity Read ↗

Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy.Semantic proximity Read ↗

Genetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma.Semantic proximity Read ↗

Effect of variation of ABCB1 and ABCC3 genotypes on the survival of bone tumor cases after chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.